APP and Anxiety: More recently, administration of tirzepatide for 8 weeks to 6-month-old APP/PS1 mice at a dose sufficient to reduce blood glucose and modulate CNS gene expression related to glucose transport, had no effect on hippocampal plaque accumulation and did not modify anxiety or cognitive function assessed by novel object recognition and MWM testing [44].